Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor

(2021) Amornrat O'Brien et al.   VIROLOGY

Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2

(2021) Jim Baggen et al.   NATURE GENETICS

A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry

(2021) Yunkai Zhu et al.   Nature Communications

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

(2021) Jerzy Osipiuk et al.   Nature Communications

Emerging coronaviruses: Genome structure, replication, and pathogenesis

(2020) Yu Chen et al.   JOURNAL OF MEDICAL VIROLOGY

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

(2020) Daniel Blanco-Melo et al.   CELL

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

(2020) David E. Gordon et al.   NATURE

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

(2020) Zhenming Jin et al.   NATURE

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

(2020) Wenhao Dai et al.   SCIENCE

The Development of Coronavirus 3C-Like Protease (3CLpro) Inhibitors from 2010 to 2020

(2020) Yuzhi Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

(2020) Laura Riva et al.   NATURE

Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography

(2020) Daniel W. Kneller et al.   Nature Communications

Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay

(2020) Heather M. Froggatt et al.   JOURNAL OF VIROLOGY

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

(2020) Wayne Vuong et al.   Nature Communications

Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks

(2020) William M. Schneider et al.   CELL

Coxsackievirus B3 Responds to Polyamine Depletion via Enhancement of 2A and 3C Protease Activity

(2019) Courtney N. Dial et al.   Viruses-Basel

Probing Morbillivirus Antisera Neutralization Using Functional Chimerism between Measles Virus and Canine Distemper Virus Envelope Glycoproteins

(2019) Miguel Angel Muñoz-Alía et al.   Viruses-Basel

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

(2019) Jesus S. Mora et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

A novel phosphoserine motif in the LCMV matrix protein Z regulates the release of infectious virus and defective interfering particles

(2016) Christopher M. Ziegler et al.   JOURNAL OF GENERAL VIROLOGY

The Lymphocytic Choriomeningitis Virus Matrix Protein PPXY Late Domain Drives the Production of Defective Interfering Particles

(2016) Christopher M. Ziegler et al.   PLoS Pathogens

Masitinib for the treatment of mild to moderate Alzheimer’s disease

(2015) Jaume Folch et al.   Expert Review of Neurotherapeutics

Masitinib for the treatment of mild to moderate Alzheimer’s disease

(2015) Jaume Folch et al.   Expert Review of Neurotherapeutics

Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings

(2013) Hyun Lee et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Masitinib (AB1010), from canine tumor model to human clinical development: Where we are?

(2013) Ilaria Marech et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Improved crystallographic models through iterated local density-guided model deformation and reciprocal-space refinement

(2012) Thomas C. Terwilliger et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

(2012) Patrick Vermersch et al.   BMC Neurology

The Tyrosine Kinase Inhibitor Masitinib Blunts Airway Inflammation and Improves Associated Lung Mechanics in a Feline Model of Chronic Allergic Asthma

(2012) Tekla M. Lee-Fowler et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

High-throughput protein purification and quality assessment for crystallization

(2011) Youngchang Kim et al.   METHODS

Molecular replacement withMOLREP

(2009) Alexei Vagin et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

MolProbity: all-atom structure validation for macromolecular crystallography

(2009) Vincent B. Chen et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics

(2009) M. Humbert et al.   ALLERGY

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

(2009) J.C. Soria et al.   EUROPEAN JOURNAL OF CANCER

Structural Basis of Inhibition Specificities of 3C and 3C-like Proteases by Zinc-coordinating and Peptidomimetic Compounds

(2009) Cheng-Chung Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors

(2009) K.A. Hahn et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

(2009) Patrice Dubreuil et al.   PLoS One

Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors

(2008) Arun K. Ghosh et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS